GO Therapeutics and Roche collaborate in new glycotargeting bispecific cancer treatment
09-Oct-2018 -
GO Therapeutics, Inc. (GO) announced that it has entered into a license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (Roche).
Under the terms of the agreement, GO will grant Roche a worldwide, exclusive license for antibodies generated to address a novel cancer-specific ...
antibodies
immunotherapies
milestone payments
+3